|
Synonyms: REGN-1979 | REGN1979
Compound class:
Antibody
Comment: Odronextamab (REGN1979) is a fully human CD3ε/CD20 bispecific IgG4-based antibody that redirects CD3+ cytotoxic T cells to selectively destroy CD20+ve malignant B cells [2]. Fc-mediated effector function has been minimised by modification of the IgG4 Fc domain.
|
| No information available. |
Summary of Clinical Use  |
| Odronextamab (REGN1979) is in clinical evaluation to determine efficacy as a treatment for advanced B cell malignancies. Early evidence of activity against heavily pretreated B cell non-Hodgkin lymphoma was reported from a phase 1 study, in 2022 [1]. It was designated as an orphan medicine for the treatment of diffuse large B cell lymphoma in the European Union in July 2022. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02290951 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | Phase 1 Interventional | Regeneron Pharmaceuticals | 1 | |
| NCT05685173 | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas | Phase 1 Interventional | Regeneron Pharmaceuticals | ||
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | Phase 2 Interventional | Regeneron Pharmaceuticals | ||
